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Abstract
Objectives—To describe the information about medication risks/benefits that rheumatologists 
provide during patient office visits, the gist that patients with rheumatoid arthritis (RA) extract 
from the information provided, and the relationship between communication and medication 
satisfaction.
Methods—Data from 169 RA patients were analyzed. Each participant had up to three visits 
audiotaped. Four RA patients coded the audiotapes using a Gist Coding Scheme and research 
assistants coded the audiotapes using a Verbatim Coding Scheme.
Results—When extracting gist from the information discussed during visits, patient coders 
distinguished between discussion concerning the possibility of medication side effects versus 
expression of significant safety concerns. Among patients in the best health, nearly 80% reported 
being totally satisfied with their medications when the physician communicated the gist that the 
medication was effective, compared to approximately 50% when this gist was not communicated.
Conclusion—Study findings underscore the multidimensional nature of medication risk 
communication and the importance of communication concerning medication effectiveness/need.
Practice implications—Health care providers should ensure that patients understand that 
medication self-management practices can minimize potential risks. Communicating simple gist 
messages may increase patient satisfaction, especially messages about benefits for well-managed 
patients. Optimal communication also requires shared understanding of desired therapeutic 
outcomes.
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1. Introduction
Rheumatoid arthritis (RA) is an incurable, systemic, autoimmune disorder affecting 
approximately 0.5–1% of adults in developed countries worldwide [1]. Despite advances in 
therapy, RA often leads to progressive joint destruction and significant functional 
impairment, affecting patients’ ability to work and perform social roles [2]. The 
inflammation caused by RA can also damage internal organs, leading to premature mortality 
[3,4]. Current guidelines call for aggressive treatment of early RA with disease-modifying 
drugs (DMARDs) to control inflammation and pain, minimize joint damage, and prevent 
loss of function [5,6].
Although individuals with RA have a variety of treatment options available to them, the 
potential benefits associated with different options are accompanied by serious risks [7,8]. 
Principles of informed consent, informed and shared decision-making, and professional 
ethics emphasize the importance of patients’ understanding the risks and benefits of all 
treatment options [9–12]. Nonetheless, research also suggests that many RA patients have a 
poor understanding of their medications [13,14], suggesting that current efforts to educate 
patients about medication risks/benefits are suboptimal.
Most patients view their physician as their primary and most trusted source of information 
about medications [15,16]. Several studies have used audio or videotapes of patient office 
visits to examine the information that physicians provide when prescribing medications [17–
21]. Findings from these studies suggest that most discussion is limited to identifying the 
medication and providing instructions pertaining to medication use (e.g., dosage). 
Discussion of medication benefits and potential side-effects occurs less frequently. Makoul, 
Arntson, and Schofield also found that both physicians and patients tend to overestimate the 
information provided [17]. Thus, patients may leave visits with an “illusion of competence,” 
unaware of their knowledge deficits.
In contrast to previous research that has focused on the verbatim information that physicians 
provide concerning medication risks and benefits, the research described in this paper was 
designed to advance understanding of how patients extract meaning from the information 
provided by physicians. The study was guided by fuzzy-trace theory, a dual-process model 
of memory, judgment, and decision making that has been used to study how both children 
and adults make decisions that involve risk [22]. Briefly, fuzzy-trace theory posits that, when 
an individual is exposed to a meaningful stimulus (e.g., a statement made by one’s 
physician), two types of representations of the stimulus are encoded in memory, a verbatim 
representation and one or more gist representations. Verbatim representations capture the 
specific wording and/or numbers as stated. Gist representations capture the bottom-line 
meaning of the statement, including its emotional meaning. People may form multiple gist 
representations in response to the same information. For example, when told that a 
medication has a 10% chance of causing liver toxicity, a patient might represent this 
Blalock et al. Page 2
Patient Educ Couns. Author manuscript; available in PMC 2017 July 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
information in memory as some risk (as opposed to no risk) and as a high (as opposed to 
low) risk. However, individuals may also fail to understand the information provided or 
make inappropriate inferences—leading to gist representations that are in conflict with 
factual information. For example, if a physician does not discuss any potential risks when 
prescribing a medication, a patient might infer that the medication has no risks, leading to 
the formation of inaccurate gist representations [23]. These representations support both 
judgments (e.g., perceived risk, satisfaction) and decisions (e.g., medication adherence).
In this paper, we examine the gist that can be extracted from the information that physicians 
provide concerning medications risks/benefits. We also examine the relationship between 
verbatim/gist communication and patient satisfaction with their current RA medication 
regimen. Satisfaction is an important mediator that links patient-provider communication to 
treatment adherence and health outcomes [24]. Finally, we also evaluate the following 
hypotheses:
1. Better health status will be associated with greater medication satisfaction;
2. Controlling for health status,
a. Gist communication emphasizing medication effectiveness (i.e., 
benefits) will be associated with greater satisfaction;
b. Gist communication emphasizing medication risks will be associated 
with lower satisfaction; and
3. The relationship between medication satisfaction and gist communication will be 
greatest when patients view their current health status favorably.
2. Methods
2.1. Data source
Data were collected between 2003 and 2007 as part of a National Institute on Aging funded 
study entitled, Older Adults and Drug Decisions: Collaboration & Outcomes. The Older 
Adults study used a randomized controlled trial design to evaluate an intervention that 
encouraged patients to talk to their doctor about their most important health concerns. 
Participants were recruited from rheumatology practices in Wisconsin and North Carolina. 
The study was limited to patients who: had a physician-confirmed diagnosis of RA; had no 
known terminal illnesses; could speak English; and were mentally competent. Clinic staff 
identified eligible patients prior to their next office visit. At the visit, a research assistant 
explained the study to the patient and obtained written, informed consent. After providing 
informed consent at baseline, each participant’s visit was audiotaped. Immediately following 
the visit, patients completed an interview and brief questionnaire. These data collection 
procedures were repeated at follow-up office visits approximately 6 and 12 months after 
baseline.
2.2. Procedures
2.2.1. Measures created via content analysis of audiotaped office visits—The 
audiotapes were transcribed to facilitate content analysis. All coding was then conducted 
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using only the transcripts. Two separate coding schemes were developed and used to analyze 
the transcripts. Because both coding schemes have been described in previous publications 
[25,26], only a brief overview is provided below. Because verbatim content is literal but gist 
content reflects interpretation, research assistants performed verbatim coding and RA 
patient-coders (who had the experience needed to interpret the information rheumatologists 
provided) performed gist coding. Whether these patient-coders interpreted information in a 
way that roughly approximated the interpretations of study participants is an empirical 
question that can be evaluated, in part, by whether coded gist predicts the judgments made 
by study participants.
Verbatim coding scheme: The Verbatim Coding Scheme captured the specific medication 
risks that the rheumatologist discussed during each visit and, for each risk, whether the 
following risk dimensions were discussed: probability of occurrence, potential severity/
impact, strategies to minimize risk, strategies to monitor risk, what to do if the risk occurs, 
time course (e.g., when the risk is most likely to occur), whether potential harm would be 
permanent or temporary, and therapeutic alternatives with different risk profiles [26]. Data 
were aggregated across risks so that each observation in the analytic dataset corresponded to 
a specific medication discussed at a specific patient visit. Each dimension was coded as “1” 
if it had been mentioned for any risk associated with the medication. Otherwise, the 
dimension was coded as “0.” Two aggregate scores were also created by: (1) summing the 
number of medication risks discussed and (2) computing the average number of dimensions 
discussed per risk.
Gist coding scheme: The Gist Coding Scheme was designed to capture the gist of 
information concerning medication risks and benefits that patients are likely to extract from 
the information that rheumatologists provide during office visits [25]. Four patients with RA 
worked with the lead author to develop this coding scheme by reviewing a subset of the 
transcripts and identifying, from the patient perspective, the important medication-related 
themes that emerged. The final coding scheme included the following gist themes: The 
medicine has some serious side-effects, The medicine is less safe than other medicines, The 
rheumatologist is concerned about the safety of the medicine for this patient, The patient can 
use the medicine as long as therapy is monitored carefully, The medicine is helping the 
patient a lot, and The patient needs the medicine a lot. Working independently, the four 
patient coders used the Gist Coding Scheme to code each transcript. Because some 
transcripts contained brief mention of several medications, coders were instructed to identify 
those medications that, in their judgment, were discussed most during the visit and were 
limited to coding no more than two medications/visit.
Ratings were combined across coders to create a final dataset where each observation 
corresponded to a specific medication discussed at a specific visit. In this dataset, each gist 
theme variable was coded as “1” if: (1) two or three coders had coded the theme and all 
agreed that it had been expressed or (2) four coders had coded the theme and at least three of 
the coders agreed that it had been expressed. Otherwise, the gist theme variable was coded 
as “0”.
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We examined correlations among the six gist theme variables to determine if a smaller 
number of composite variables could be identified. Two of the gist theme variables, The 
medicine is helping the patient a lot and The patient needs the medicine a lot, were strongly 
correlated. Therefore, a composite variable, labeled Medication is Effective, was created and 
set to “1” if either of these themes was mentioned; otherwise, it was set to “0”. The internal 
consistency of this measure, assessed by the Kuder–Richardson Formula 20, ranged from 
0.96 to 0.97 across the three visits. Three other themes strongly correlated with one another: 
The medicine has some serious side-effects, The medicine is less safe than other medicines, 
and The rheumatologist is concerned about the safety of the medicine for this patient. 
Therefore, a second composite variable, labeled Medication Has Risks, was created and set 
to “1” if any of these themes was mentioned; otherwise, it was set to “0.” The internal 
consistency of this measure ranged from 0.76 to 0.79 across visits. Correlations between the 
two composite variables ranged from −0.11 to −0.28 across the three visits. The remaining 
individual gist theme variable, The patient can use the medicine as long as therapy is 
monitored carefully, exhibited relatively low correlations with the other gist themes, ranging 
from −0.15 to 0.22 across the three visits.
2.2.2. Measures obtained from patient interviews and questionnaires—Health 
status was assessed by a composite measure that included: the pain, tension, and mood 
subscales (total of 14 items) from the Arthritis Impact Measurement Scales 2 [27]; an item 
that asked patients to rate their pain during the previous 24 h on a visual analog scale with 
endpoints labeled, 0 = No pain, 10 = Worst pain ever; and an item that asked patients to rate 
their health on a 5-point scale ranging from 1 = Poor to 5 = Excellent. The individual items 
were reverse scored as needed so that higher values would correspond to better health status 
and standardized (mean = 0; standard deviation = 1). Unweighted item scores were summed 
to yield the final composite measure. Cronbach’s alpha for this measure exceeded 0.90 at all 
visits.
Medication satisfaction was assessed after each office visit via interview by asking 
patients: “How satisfied are you with the medicines you are supposed to take until your next 
visit?” Responses were recorded on a 5-point response scale where,1 = Not at all, 2 = A 
little, 3 = Somewhat, 4 = Very, and 5 = Totally. Because over 50% of participants reported 
being Totally Satisfied, this variable was dichotomized as 0 = Not totally satisfied and 1 = 
Totally satisfied.
Medication regimen changes: Following each visit, patients were asked if they had 
discussed any changes in their medication regimen during the visit. This variable was coded 
as 1 if changes had been discussed; otherwise, it was coded as 0. Patients were also asked if 
any new medications had been prescribed at the visit. This variable was coded as 1 if a new 
medication was prescribed; otherwise, it was coded as 0.
Sociodemographic characteristics: Patient gender, age, race (0 = Non-white, 1 = White), 
and education (0 = High school graduation or less, 1 = Education beyond high school), 
marital status, and income were assessed at baseline.
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2.3. Data analyses
All analyses were performed using PC-SAS [28]. Together, the patient coders coded a total 
of 2076 medications. However, there was wide variability among the coders in terms of the 
specific medications coded and the gist themes extracted [25]. Therefore, to create reliable 
gist theme measures, medications coded by only one coder were eliminated and a variable 
indexing inter-rater agreement was created for each gist theme. This variable was set to “1” 
if: (1) two or three coders had coded the medication and all agreed that the theme either had 
or had not been expressed or (2) four coders had coded the medication and at least three of 
the coders agreed that the theme either had or had not been expressed. Otherwise, the 
agreement variable was set to “0”. A measure of Gist Clarity was then created by computing 
the average level of inter-rater agreement across the six gist themes. This variable ranged 
from 0% to 100%. The dataset was restricted to 428 medications with Gist Clarity scores of 
at least 75%.
Descriptive statistics were used to summarize the characteristics of study participants and 
the types of communication concerning medication risks/benefits that occurred during visits. 
Phi coefficients were used to examine bivariate relationships between the verbatim and gist 
communication variables. However, statistical significance was evaluated using generalized 
estimating equations (GEE) because the dataset included multiple observations per 
participant [29]. In the GEE analyses, observations were clustered by patient. The GEE 
models specified an exchangeable working correlation matrix which assumes that all within 
cluster correlations are equal.
GEE was also used to test the hypothesized relationships between medication satisfaction 
and (a) health status and (b) the gist communication variables. In these analyses, 
observations were aggregated by office visit and the gist communication variables were 
coded as present if they had been coded as present for any of the medications discussed 
during the visit. A 6-step hierarchical logistic regression model predicting medication 
satisfaction was used. Variables were added to the model in the following order, Step 1: 
sociodemographic characteristics, Step 2: health status, Step 3: medication regimen change 
variables, Step 4: verbatim communication variables, Step 5: gist communication variables, 
and Step 6: 2-way interaction terms representing the interaction between the gist 
communication variables and health status. Only the composite verbatim and gist variables 
were included in the model to reduce complexity and avoid potential problems due to 
multicollinearity. The model used an exchangeable correlation matrix with observations 
clustered by patient. Observations with missing values were excluded from the hierarchical 
regression and assumed to be missing at random. Statistical significance was evaluated with 
alpha set at 0.05.
3. Results
3.1. Characteristics of study participants
Data from 169 participants were included in the restricted dataset. The mean age (SD) of 
participants was 61.3 years (SD = 10.0). Most were married (66.7%), white (92.2%), 
females (79.9%), and in Stage II (56.6%) of the ACR revised criteria for the classification of 
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global functional status [30]. Median income was $40,000–$59,000 (US) and 38.2% of 
participants had no education beyond high school. Participants were seen by a total of 13 
rheumatologists. Mean rheumatologist age was 47.6 years (SD = 7.3). Most were white 
(84.6%) and nearly half (46.2%) were female.
3.2. Medications discussed
A total of 427 medications discussed during the visits were coded. Most of the medications 
discussed were DMARDs. These included: biologics (n = 111), methotrexate (n = 83), 
hydroxychloroquine (n = 22), and leflunomide (n = 18). Other commonly discussed 
medications were: prednisone (n = 67), nonsteroidal anti-inflammatories (n = 46), and 
narcotic analgesics (n = 13).
3.3. Gist themes and verbatim information discussed
As shown in Table 1, the gist themes most commonly extracted by the patient coders were: 
The patient needs the medicine and The medicine is helping the patient. The Verbatim 
Coding Scheme revealed that an average of 1.46 (SD = 1.71) risks were discussed per 
medication and that 0.96 (SD = 2.02) dimensions were discussed per medication risk. The 
most commonly discussed risk dimensions involved things the patient could do to minimize 
risk and procedures to monitor therapy to detect early warning signs of a problem.
3.4. Relationship between verbatim and gist communication variables
As shown in Table 2, three of the individual gist themes that pertained to medication safety 
(i.e., The medicine has some serious side-effects, The rheumatologist is concerned about the 
safety of the medicine, and The medicine is less safe than other medicines) were consistently 
associated with verbatim discussion of: (1) risk severity/impact, (2) things the patient could 
do to minimize risk, and (3) therapeutic alternatives to avoid the risk, with correlations 
ranging from 0.24 to 0.39. Two of the individual gist themes (i.e., The medicine has some 
serious side-effects and The patient can use the medicine as long as therapy is monitored 
carefully) were associated with verbatim discussion of the importance of monitoring to 
detect potential problems early. Finally, the two individual gist themes that pertained to 
medication effectiveness and need were negatively associated with discussion of: (1) things 
the patient could do to minimize the risk and (2) therapeutic alternatives to avoid the risk. 
Table 2 also shows correlations between the verbatim risk dimensions and the two composite 
gist themes. The pattern of correlations observed paralleled those for the individual gist 
themes.
3.5. Regression analyses predicting medication satisfaction
Table 3 shows the bivariate associations between medication satisfaction and all of the 
predictor variables included in the hierarchical regression model. Better health was 
associated with greater medication satisfaction (OR = 1.49, p = 0.01); whereas, initiation of 
a new medication and discussion of a regimen change were associated with lower 
satisfaction (OR’s = 0.45 and 0.61, respectively, both p’s <0.01). In the hierarchical logistic 
regression model predicting medication satisfaction (Table 4), the interaction between the 
Medication is Effective gist communication variable and health was statistically significant 
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(OR = 2.22, 95% CI = 1.07 to 4.64, p = 0.04). This term tested the prediction that the 
relationship between the gist communication variables and medication satisfaction would 
depend on patient health status. To evaluate the nature of this interaction, we stratified the 
sample into quartiles using participant scores on the health status measure. As shown in Fig. 
1, among people in the quartile with the best health, participants were more likely to report 
being totally satisfied with their medications when the gist that the Medication is Effective 
was communicated than when this gist was not communicated. Among people in the other 
three quartiles, medication satisfaction did not vary across groups.
4. Discussion and conclusion
4.1. Discussion
The findings reported in this paper provide a comprehensive assessment of the information 
concerning medication risks and benefits that physicians provide during RA patient office 
visits and the gist that patients extract from this information. This is important because gist 
understanding has been identified as crucial for informed decision making [23]. Several 
important findings warrant highlighting.
First, most discussion concerning medication risks was superficial. Although at least one 
medication side-effect was mentioned for most of the medications coded, at least one risk 
dimension was mentioned for only 36% of these medications. This finding is consistent with 
previous research which has found that most medication-related discussion during patient 
office visits involves the physician identifying the medication and telling the patient how to 
use it [17–20]. Together, these findings suggest the existence of a wide gap between current 
practice and normative models of medical decision making that call for a thorough 
discussion of the risks and benefits associated with all treatment options [31].
Second, the patient coders often had difficulty discerning the gist that the rheumatologists 
were attempting to convey during the visits analyzed. Only 35.8% of the medications coded 
by at least two patient coders had gist clarity scores at or above 0.75. This may be due, at 
least in part, to the minimal discussion of medication risks/benefits that occurred during 
most visits. When minimal information is provided, individuals are forced to “read between 
the lines” to extract bottom-line gist meaning, leading to greater variability across 
individuals and opening the door for misunderstandings that compromise therapy.
Third, the pattern of associations between the verbatim and gist communication variables 
provide clues as to how patients extract gist from the information that physicians provide 
concerning medication risks/benefits. For example, discussion of the importance of 
monitoring was associated with patient extraction of two gist themes: The medicine has 
some serious side-effects and The patient can use the medicine as long as therapy is 
monitored carefully. However, it was not associated with extraction of the gist themes that 
captured significant physician concerns about medication safety: Doctor has safety concerns 
and Medicine is less safe than other medicines. Thus, when extracting gist from the 
information discussed during visits, the patient coders distinguished between discussion 
concerning the possibility of medication side-effects versus expression of significant safety 
concerns. In addition, provision of information concerning risk probability was minimally 
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correlated with any of the gist communication variables. This is particularly striking because 
the vast majority of research on risk communication concerns how best to convey 
probabilistic information. These findings underscore the importance of clear communication 
concerning other risk dimensions (e.g., strategies to minimize risk) as well.
Fourth, we found partial support for predictions concerning the relationship between 
medication satisfaction and (a) patient health status and (b) communication concerning 
medication risks/benefits. As predicted, the relationship between medication satisfaction and 
gist communication concerning medication effectiveness depended on patient health status. 
Among patients in better health, medication satisfaction was greater when the physician 
communicated the gist that the Medication is effective. From the perspective of fuzzy-trace 
theory, communicating medication-effectiveness gist clearly can help patients make the 
connection between improved health status and the receipt of effective therapy. Among 
patients in poorer health, medication satisfaction did not vary as a function of whether 
medication effectiveness gist was communicated. In this case, patients who perceive their 
health negatively are likely to reject physicians’ communication emphasizing medication 
effectiveness. However, we did not find the predicted interaction between gist 
communication concerning medication risks and health status. This prediction was based on 
the assumption that health status and medication satisfaction would be positively correlated 
in the absence of medication safety concerns and that discussion of medication risks would 
weaken this association. Although health status and medication satisfaction were positively 
correlated, we found no evidence that discussion of medication risks weakened this 
association.
Several study limitations should be noted. The patients who coded the transcripts using the 
Gist Coding Scheme were not the same patients whose office visits were audiotaped. In 
addition, the coders worked from written transcripts of the visits. Thus, they could not hear 
the tone of voice that patients and rheumatologists used when discussing medication risks/
benefits or observe information communicated nonverbally. Most patients in the study had a 
long-term relationship with their rheumatologist and were on stable medication regimens. 
These factors would likely attenuate relationships observed between the communication 
variables and medication satisfaction. Finally, analyses were limited to discussions of 
medications in which the gist communicated by the rheumatologist was clear as indicated by 
consistency in the gist themes extracted by the four patient coders. Examining the effect that 
less clear communication may have on patient satisfaction and decision making remains an 
important area for future research.
4.2. Conclusion
Most research on medication risk/benefit communication has focused on the effects that 
written information has on patient knowledge and decision making. Studying medication 
risk/benefit communication within the context of the patient-provider relationship is 
considerably more complex. Our findings demonstrate the feasibility of using fuzzy-trace 
theory to better understand the gist that patients extract from the information concerning 
medication risks/benefits that physicians provide during office visits. Our findings also 
underscore the importance of considering the multiple risk dimensions (e.g., controllability) 
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that can affect the gist that patients extract from information concerning medication risks/
benefits.
4.3. Practice implications
Study findings highlight the multidimensional nature of medication risk communication. 
When discussing medication risks with patients, health care providers should ensure that 
patients understand how medication self-management practices (e.g., obtaining 
recommended laboratory monitoring) can minimize the potential for harm. Study findings 
also highlight the importance of communication concerning medication effectiveness and 
need. Health care providers should ensure that patients understand the clinical criteria they 
use when evaluating medication effectiveness. At the same time, health care providers must 
recognize that patients may evaluate therapy using different criteria [32,33]. Optimal 
communication requires a shared understanding of desired therapeutic outcomes.
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Fig. 1. 
Percentage of participants totally satisfied with medication by whether medication 
effectiveness gist is communicated.
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Table 1
Prevalence of risk/benefit communication during office visits (N = 428).
Gist themes extracteda % (n)
The medicine is needed a fair amount or a lot. [ICC: 0.72] 36.7 (157)
The medicine is helping (or would help) a fair amount or a lot. [ICC: 0.75] 34.4 (147)
The patient can use the medicine as long as therapy is monitored carefully. [ICC: 0.83] 25.5 (109)
The medicine has some serious side-effects. [ICC: 0.62] 23.4 (100)
Doctor is concerned about the safety of the medicine a fair amount or a lot. [ICC: 0.80] 13.2 (47)a
Medication is less safe than other medications. [ICC: 0.68] 6.8 (29)
Verbatim information discussed
At least one medication side-effect discussed 64.0 (274)
At least one risk dimension discussed 36.0 (154)
What to do to minimize the risk [ICC: 0.61] 19.9 (85)
Importance of monitoring to detect potential problems early [ICC: 0.90] 18.0 (77)
Probability [ICC: 0.79] 6.8 (29)
Potential severity/impact [ICC: 0.53] 6.3 (27)
Therapeutic alternatives to avoid the risk discussed [ICC: 0.62] 5.8 (25)
Time course of risk [ICC: 0.74] 4.2 (18)
What to do if the risk occurs [ICC: 0.75] 3.5 (15)
Whether potential harm would be permanent or temporary [ICC: 0.85] 0.7 (3)
Note: ICC: Intraclass correlation coefficients calculated based on medications coded by all four gist coders. The dataset included observations 
involving 428 medications taken by 169 patients.
a
Based on 356 observations because this theme was added after coding started.
Patient Educ Couns. Author manuscript; available in PMC 2017 July 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Blalock et al. Page 15
Ta
bl
e 
2
Co
rre
la
tio
ns
 b
et
w
ee
n 
gi
st 
th
em
es
 a
nd
 v
er
ba
tim
 ri
sk
 d
im
en
sio
ns
 (N
 
=
 4
28
).
Ve
rb
at
im
 r
isk
 d
im
en
sio
ns
 
di
sc
us
se
d
So
m
e s
er
io
us
 si
de
-e
ffe
ct
s
D
oc
to
r 
ha
s 
sa
fe
ty
 
co
n
ce
rn
sa
In
di
v
id
ua
l g
ist
 th
em
es
C
om
po
sit
e g
ist
 th
em
es
Le
ss
 sa
fe
 
th
an
 o
th
er
 
m
ed
ic
in
es
Sa
fe
 if
 
m
o
n
ito
re
d 
ca
re
fu
lly
M
ed
ic
in
e 
is 
he
lp
in
g 
pa
tie
nt
Pa
tie
nt
 n
ee
ds
 m
ed
ic
in
e
M
ed
ic
at
io
n 
ha
s r
isk
s
M
ed
ic
at
io
n 
is 
ef
fe
ct
iv
e
Pr
ob
ab
ili
ty
0.
16
0.
03
0.
00
0.
10
0.
04
0.
05
0.
17
*
0.
04
Im
po
rta
nc
e 
of
 m
on
ito
rin
g
0.
29
*
*
0.
05
−
0.
01
0.
47
*
*
0.
06
0.
10
0.
28
*
*
0.
10
Po
te
nt
ia
l s
ev
er
ity
/im
pa
ct
0.
29
*
*
0.
32
*
*
0.
31
*
0.
07
−
0.
05
−
0.
02
0.
32
*
*
−
0.
02
W
ha
t t
o 
do
 to
 m
in
im
iz
e 
th
e 
ris
k
0.
24
*
*
0.
37
*
*
0.
29
*
−
0.
14
*
−
0.
22
*
*
−
0.
21
*
*
0.
27
*
*
−
0.
22
*
*
Th
er
ap
eu
tic
 a
lte
rn
at
iv
es
 to
 
av
o
id
 th
e 
ris
k 
di
sc
us
se
d
0.
31
*
*
0.
39
*
*
0.
33
*
*
−
0.
08
−
0.
16
*
*
−
0.
17
*
*
0.
32
*
*
−
0.
17
N
ot
e:
 
Th
e 
da
ta
se
t i
nc
lu
de
d 
ob
se
rv
at
io
ns
 in
v
o
lv
in
g 
42
8 
m
ed
ic
at
io
ns
 ta
ke
n
 b
y 
16
9 
pa
tie
nt
s. 
Va
lu
es
 p
re
se
nt
ed
 a
re
 p
hi
 c
oe
ffi
ci
en
ts.
 p
-
Va
lu
es
 a
re
 b
as
ed
 o
n 
ge
ne
ra
liz
ed
 e
sti
m
at
in
g 
eq
ua
tio
ns
 w
ith
 o
bs
er
va
tio
ns
 
cl
us
te
re
d 
by
 p
at
ie
nt
.
a B
as
ed
 o
n 
35
6 
ob
se
rv
at
io
ns
 b
ec
au
se
 th
is 
th
em
e 
w
as
 a
dd
ed
 a
fte
r c
od
in
g 
sta
rte
d.
*
p 
<
0.
00
1.
*
*
p 
<
0.
00
01
.
Patient Educ Couns. Author manuscript; available in PMC 2017 July 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Blalock et al. Page 16
Table 3
Bivariate associations between medication satisfaction and predictor variables (N = 383).
Predictor variables n OR 95% CI p
Sociodemographics
 Age 380 1.02 0.99–1.04 0.16
 Race (Reference group: white) 372 1.13 0.56–2.30 0.73
 Gender (Reference group: female) 380 0.80 0.46–1.39 0.42
 Education (Reference group: beyond high school) 369 1.39 0.87–2.21 0.17
Health status
 Health 372 1.49 1.10–2.02 0.01
 Medication regimen
 Initiation of a new medication 380 0.45 0.27–0.75 0.002
 Discussed a regimen change 380 0.61 0.41–0.91 0.01
Verbatim communication variables
 # of risks discussed 380 0.92 0.76–1.11 0.39
 Average # of dimensions discussed/risk 380 1.12 0.92–1.36 0.28
Gist communication variables
 Medication has risks 380 0.77 0.50–1.19 0.24
 Medication is effective 380 1.45 0.95–2.20 0.08
Note: Data were aggregated by visit, resulting in 383 observations. Number of observations vary across predictor variables due to missing data. 
Analysis performed using generalized estimating equations with observations clustered by patient.
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Table 4
Hierarchical logistic regression models predicting satisfaction with medication (N = 363).
Step Predictor variables OR 95% CI p
1 Sociodemographics
Age 1.01 0.99–1.04 0.31
Race (Reference group: white) 1.10 0.49–2.45 0.82
Gender (Reference group: female) 0.77 0.43–1.39 0.39
Education (Reference group: beyond high school) 1.32 0.82–2.13 0.25
2 Health status
Health 1.51 1.08–2.12 0.02
3 Medication regimen
Initiation of a new medication 0.59 0.34–1.01 0.05
Discussed a regimen change 0.72 0.47–1.09 0.12
4 Verbatim communication variables
# of risks discussed 0.96 0.86–1.08 0.53
Average # of dimensions discussed/risk 1.35 0.97–1.88 0.08
5 Gist communication variables
Medication has risks 0.87 0.50–1.51 0.62
Medication is effective 1.58 1.00–2.48 0.05
6 Two way interaction terms
Health × gist risks 0.69 0.31–1.53 0.36
Health × gist effectiveness 2.22 1.07–4.64 0.04
Note: Data were aggregated by visit, resulting in 383 observations. 20 observations with missing data were not included in the analyses. Analysis 
performed using generalized estimating equations with observations clustered by patient.
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